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 Neonatal jaundice can be best understood as a balance between the production 
and elimination of bilirubin, with a multitude of factors and conditions affecting 
each of these processes. When an imbalance results because of an increase in cir-
culating bilirubin (or the bilirubin load) to significantly high levels (severe hyperbi-
lirubinemia), it may cause permanent neurologic sequelae (kernicterus). In most 
infants, an increase in bilirubin production (e.g., due to hemolysis) is the primary 
cause of severe hyperbilirubinemia, and thus reducing bilirubin production is a 
rational approach for its management. The situation can become critical in infants 
with an associated impaired bilirubin elimination mechanism as a result of a genetic 
deficiency and/or polymorphism. Combining information about bilirubin production 
and genetic information about bilirubin elimination with the tracking of bilirubin 
levels means that a relative assessment of jaundice risk might be feasible. 
Information on the level of bilirubin production and its rate of elimination may help 
to guide the clinical management of neonatal jaundice. 
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 1. Etiology of Neonatal Jaundice 
 Neonatal jaundice is usually a normal physiologic 
condition occurring during the transitional period 
after birth. It is not a singular disease in itself, but 
a physical finding associated with multiple possi-
ble etiologies. Severe neonatal jaundice is consid-
ered to be pathophysiologic. Jaundice reflects the 
accumulation of the yellow-orange pigment biliru-
bin in the skin, sclerae, and other tissues; it does 
not imply any particular causation. Thus, preventive 
and therapeutic approaches to pathophysiologic 
neonatal jaundice or hyperbilirubinemia have typi-
cally been nonspecific. They include phototherapy 
and blood exchange transfusions, both of which fa-
cilitate the removal of bilirubin after it has been 
produced in the body. More specific or targeted 
approaches require a better understanding of the 
pathophysiology involved in each individual case. 
 The production of bilirubin as a result of the 
degradation of heme arising from normal red blood 
cell (RBC) turnover is a normal part of our physiol-
ogy. The first step in this two-step process is an 
ancient one in the biology of this planet; it occurs 
in both plants and animals. In the first step, heme 
is catalyzed by the membrane-associated enzyme, 
heme oxygenase (HO). 1 There are at least two forms 
of this enzyme: HO-1, the inducible form, and HO-2, 
the constitutive form. 2 The ratio between the two 
forms varies in different tissues. It is possible that 
a third form also exists, but much less is known 
about this protein. 3 The first enzymatic step requires 
molecular oxygen (O 2 ) and NADPH donated from the 
cytochrome P450 system (Figure 1  4). It involves a 
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series of oxidations and reductions, ultimately lead-
ing to the breakage of the α-methene bridge of the 
heme ring, releasing carbon monoxide (CO) and fer-
rous iron (Fe + + ), giving rise to the green pigment, 
biliverdin. In most mammals, biliverdin is rapidly 
reduced in the cytosol by biliverdin reductase in 
the presence of NADPH to produce the yellow pig-
ment, bilirubin. CO, Fe + + and bilirubin are produced 
in equimolar amounts. Therefore, based on this sto-
ichiometry and in the absence of any other source 
of bilirubin, CO production can serve as an index 
of bilirubin production. 5 CO diffuses from the cell, 
binds to hemoglobin (Hb), thereby forming carboxy-
hemoglobin. This complex then circulates to the 
lungs, where the CO is exchanged for oxygen and 
then excreted in breath. End-tidal CO (ETCO) 6 or the 
excretion rate of CO (VeCO) 5,7 can therefore be used 
to estimate total bilirubin production in neonates. 
 Once produced, bilirubin is normally conjugated 
and then excreted via the liver. It is transported in 
the bloodstream bound to albumin, and is actively 
transported across the sinusoidal cell membrane of 
hepatocytes facing the blood stream (space of Disse). 
Once inside hepatocytes, it is conjugated with glu-
curonic acid to form bilirubin glucuronide, also 
known as either “conjugated” or “direct” bilirubin. 
The enzyme bilirubin uridine diphosphate glucuron-
osyltransferase (bilirubin UGT; UGT1A1) does this 
by a two-step process, producing bilirubin mono-
glucuronide first, and following a second glucu-
ronidation, producing bilirubin diglucuronide. The 
conjugated bilirubin is then transported across the 
canalicular membrane into the biliary tree by spe-
cific proteins, most notably multidrug resistance-
associated protein 2. Conjugated bilirubin proceeds 
down the biliary tree to the lumen of the gut for 
excretion. Newborn infants, particularly premature 
ones, have an immature bilirubin conjugation and 
excretion system. 
 Neonatal jaundice can be understood by anal-
ogy with a sink (Figure 2 8). The turned-on spigot 
represents the process of bilirubin production, and 
the drain represents the process of bilirubin elimi-
nation. If the rate at which bilirubin is produced 
exceeds the rate at which it is eliminated, then 
the level in the sink begins to rise. In this analogy, 
the sink represents the circulation and the capac-
ity of the sink is determined largely by how much 
bilirubin can be bound to albumin. However, bi-
lirubin is always moving from the circulation into 
the tissues, depending on the binding conditions. 
Therefore, the amount of albumin in the circula-
tion is relevant, but the affinity of albumin for bi-
lirubin is also a factor, with lower affinity reducing 
the amount of bilirubin retained in circulation. 
 The bilirubin load in the body is thus the result 
of the imbalance between bilirubin production and 
elimination. 9 Neonatal jaundice reflects an increase 
in total body bilirubin load after birth, but the ap-
parent or “visible” jaundice is not a good predictor 
of the level of bilirubin in circulation or the amount 
of bilirubin in the various tissues. Because bilirubin 
can have toxic effects under some conditions, its 
levels need to be closely monitored in the first 
weeks after birth. 
 2. Role of Carbon Monoxide 
 Nature has two dispositions, one that is toxic and 
one that is beneficial, and under physiologic con-
ditions, are usually balanced. For example, in the 
case of heme degradation, its products can be 
characterized as toxic: bilirubin can cause neuro-
logic disturbances, such as acute bilirubin enceph-
alopathy that can result in permanent damage or 
kernicterus and occasionally death;10 CO can cause 
mitochondrial dysfunction and death; Fe + + can gen-
erate reactive oxygen species and contribute to oxi-
dative injury. However, these same products can 
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Figure 1 Heme degradation pathway. The turnover of 
hemoglobin and other hemoproteins yields heme, which is 
metabolized to equimolar quantities of carbon monoxide 
(CO), iron (Fe++) and biliverdin. Biliverdin is subsequently 
reduced to form bilirubin. Modified and reproduced with 
permission from Reference 4.
Bilirubin
elimination
Bilirubin
production
Neonatal jaundice
Figure 2 Diagram of bilirubin production and elimina-
tion. Reproduced with permission from Reference 8.
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be characterized differently as having a variety of 
important roles in biology. The biliverdin/bilirubin 
oxidation-reduction shuttle plays an important role 
in antioxidant defense. 11 CO has a myriad of effects, 
including vessel relaxation through several possible 
mechanisms, 12−14 inhibition of platelet aggregation, 15 
and anti-apoptotic and anti-proliferative effects. 16 
It may also inhibit pro-inflammatory cytokines, 17,18 
and play a role in neurotransmission. 19,20 Moreover, 
the interactions between the HO/CO and nitric 
oxide synthase/nitric oxide systems are especially 
complex, and may involve both positive and nega-
tive effects. 16 Finally, iron is an essential element 
for much of life on the planet. 
 Under most of the conditions encountered in the 
newborn, the predominant endogenous source of CO 
(about 80%) comes from the degradation of heme, 
with 70% arising from RBC senescence, approxi-
mately 10% from ineffective erythropoiesis and 20% 
from the degradation of other hemoproteins. None-
theless, it is important to recognize other potentially 
important sources of this gas, including photo-
oxidation 21,22 and lipid peroxidation. 23 Only 14% of 
CO or less typically comes from lipid peroxidation 
and photo-oxidation, although these sources become 
more significant under certain conditions, such as 
oxidation or light exposure. 21,22 
 Bilirubin production has been estimated in a va-
riety of species by measuring CO production. Vari-
ous methods have been used for this purpose, but 
gas chromatography using a reduction gas detector 
is one of the most sensitive methods. 24 Heme ad-
ministered as damaged RBCs can be recovered com-
pletely as CO over a timeframe, reflecting splenic 
sequestration, RBC breakdown and heme catabolism. 
The same technology has been used in human stud-
ies; however, because the other sources of CO can-
not be known precisely, VeCO or ETCO measurements 
should only be considered as an index of total bi-
lirubin production. Despite this limitation, such 
measurements can be useful for identifying differ-
ences in bilirubin production between infants and 
adults, and in infants with conditions such as he-
matoma, polycythemia, hemolysis and having a di-
abetic mother. VeCO measurements are not easily 
performed in the clinical setting. However, mea-
surements of ETCO corrected for ambient CO are a 
good index of the CO production rate and corre-
late well with the carboxyhemoglobin corrected for 
ambient CO as well. 6,25−27 The distribution of cor-
rected ETCO values has been described previously, 
with easy identification of babies outside the nor-
mal distribution. 6,28 It is technically possible to pro-
duce a handheld device for commercial use that 
would provide accurate, reliable as well as rapid 
and easy bedside end-tidal breath sampling for es-
timating CO production as an index of bilirubin 
production. An infant could then be classified as 
"high" or "low" jaundice risk on the basis of an in-
creased bilirubin load. Finally, the hour-specific 
total serum bilirubin nomogram reflects increased 
production of bilirubin in the context of impaired 
elimination, with the highest risk zones reflecting 
increased bilirubin loads often observed in infants 
with increased bilirubin production rates. 29 Infants 
with hemolysis or other causes of increased bi-
lirubin production are those most likely to demon-
strate a trajectory that enters the risk zone early. 
Other infants appear to enter the risk zone over a 
longer period of time with low or normal bilirubin 
production, suggesting impaired conjugation. The 
worst-case scenario is of an infant with the combi-
nation of increased production and impaired elimi-
nation, with an unpredictable trajectory depending 
upon the degree of imbalance (Table 1). 9 
 3.  Diagnosis and Management of 
Neonatal Jaundice 
 Clinically, the differential diagnosis of neonatal 
jaundice varies during the first weeks of life. For 
instance, because virtually all neonates have de-
creased conjugation and excretion capabilities at 
birth, hyperbilirubinemia in the first 1−3 days of 
life almost always reflects an increase in bilirubin 
production. 30,31 Unconjugated hyperbilirubinemia 
on day 1 generally reflects hemolysis, usually due to 
minor blood-type incompatibilities such as rH or 
Kell, or intrauterine infection. Less commonly, the 
increase in bilirubin production may be due to a 
large hematoma (e.g., subcapsular hepatic or sub-
galeal). Jaundice presenting from days 3−7 more of-
ten reflects more modest increases in production, 
such as those associated with ABO incompatibilities 
or maternal diabetes. This is also the time when 
problems with an impaired ability to upregulate 
conjugation start to appear; the classic form of this 
is Gilbert's disease, where there is impaired UGT1A1 
activity. When combined with even modest increases 
in production such as those seen with glucose-
6-phosphate dehydrogenase (G6PD)-deficiency, the 
consequences can be devastating, with a dramatic 
and rapid rise in bilirubin levels. Infants with de-
creased food intake, and thus decreased stooling, 
Table 1  Jaundice risk profiles based on an infant's 
rates of bilirubin production and elimination
 Fast eliminator Slow eliminator
Low producer Low risk Medium risk
High producer Medium risk High risk
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may also present with increased jaundice at this 
time, because of the increased re-uptake of excreted 
bilirubin by the intestines (enterohepatic circulation 
of bilirubin). This is seen with so-called “breast-
feeding failure jaundice”, when an infant's milk in-
take is too low. Jaundice presenting after the first 
week of life rarely represents increased bilirubin 
production (more flow at the spigot), but rather im-
plies decreased excretory ability (prolonged inability 
to open the drain). This is when problems with liver 
disease and biliary obstructions tend to present. 
Failure to recognize this transition represents a se-
rious clinical error: once jaundice persists beyond 
7−10 days, and certainly beyond 14 days, conjugated 
hyperbilirubinemia must be considered and ruled-
out to avoid delaying the diagnosis of biliary atresia. 
 Because increased bilirubin production is a con-
tributory factor in all kinds of neonatal hyper-
bilirubinemia, modulation of bilirubin production 
represents a rational approach to managing the 
condition. 32,33 The target is HO, although it is im-
portant to understand that this target is not singular 
but part of a biochemical system with connections 
to other important biological processes through the 
products of the heme catabolic pathway (Figure 1). 4 
Thus, inhibition of HO as a means of controlling 
bilirubin production must be considered in the 
context of its other potential ramifications. A vari-
ety of metalloporphyrins (heme analogs) have been 
investigated as competitive inhibitors of the HO 
reaction. 34,35 The most well studied compounds in-
clude tin protoporphyrin, tin mesoporphyrin, 35 zinc 
protoporphyrin, zinc deuteroporphyrin bis glycol, 36 
and chromium mesoporphyrin. Even the naturally 
occurring zinc protoporphyrin, which has a physio-
logic role, can be used as a pharmacologic inhibitor 
of HO. In Rhesus monkeys with neonatal jaundice 
exacerbated by hemolysis, increased bilirubin pro-
duction can be lowered to native production rates 
and hyperbilirubinemia ameliorated following met-
alloporphyrin administration. Criteria have been 
developed for potential antihyperbilirubinemia 
drugs. 34,35 These criteria include the following: bio-
compatible central metal, potent HO inhibition, 
negligible degradation, negligible inhibition of other 
enzymes (such as soluble guanylyl cyclase and ni-
tric oxide synthase), 37 negligible photoreactivity, 21,34 
optimal duration of action (several days), and neg-
ligible HMOX-1  (HO-1 gene) upregulation.  In vivo bi-
oluminescence imaging has been used to investigate 
the upregulation of HMOX-1 in response to compet-
itive inhibition of the protein. 38−42 The HO-1- luc trans-
genic mouse model has been used for this purpose 
(Figure 3). 43 Such studies have revealed that met-
alloporphyrins differ in their abilities to inhibit HO 
and upregulate HMOX-1. 39,40,42 For example, tin mes-
oporphyrin is a potent inducer of HMOX-1, despite 
Luciferin Oxyluciferin*
Luciferase
Light
HMOX-1 promoter Luciferase gene
Figure 3 HO-1-luc mouse. The reporter mouse contains 
a transgene consisting of the full-length (15 kb) HMOX-1 
promoter driving expression of the reporter gene, luci-
ferase (luc). This model allows us to monitor changes in 
HMOX-1 transcription noninvasively through proportional 
changes in luciferase activity. When luciferin is adminis-
tered, it is rapidly converted to oxyluciferin by luciferase, 
resulting in the production of light. Light emission, or 
bioluminescence, therefore reflects luciferase transcrip-
tion and, hence, HMOX-1 transcriptional activity.
its inhibitory potency. 35 Zinc deuteroporphyrin bis 
glycol and chromium mesoporphyrin are nearly 
as potent, but cause minimal upregulation of the 
HMOX-1 system at effective inhibitory doses. 40,44 
They have other attractive properties as well, such 
oral absorption, which make them possible alter-
native drugs for clinical use. 
 Although bilirubin production is a rational target 
for the management of neonatal hyperbilirubine-
mia, bilirubin elimination is an equally important 
factor in the clinical equation. Kaplan et al 45 dem-
onstrated that in G6PD-deficient neonates only 
the ones with impaired conjugation became hyper-
bilirubinemic, even in the absence of a crisis. Thus, 
the intersection of increased production and im-
paired elimination creates the most dangerous 
scenario. 46,47 The genetic vulnerability created by 
G6PD-deficiency and Gilbert's disease, a polymor-
phism involving TATA repeats in the promoter of 
the UGT1A1 gene, represents a real danger to the 
newborn. 48−50 Thus, genetic information on poly-
morphisms affecting jaundice could be clinically 
useful, given it was available in a timely manner. For 
example, information about the TATA repeats in the 
HMOX-1 promoter might provide information about 
the propensity for bilirubin production, with larger 
expansions being associated with lower production 
of the protein. In addition, polymorphisms involving 
UGT1A1 or multidrug resistance-associated protein 
would be important for understanding the likelihood 
of impaired elimination. 51,52 A relative assessment 
of jaundice risk might be possible by looking for 
the intersection between low/high production and 
fast/slow elimination. It is possible that combining 
prenatal genetic information with postnatal infor-
mation on bilirubin production and the tracking of 
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bilirubin levels could shift the management of 
neonatal jaundice to a preventive strategy. 
 In summary, like all of nature, the heme degra-
dation pathway has two potential dispositions: for 
the clinician, the potentially toxic disposition is 
that of concern. However, it is important to under-
stand that the pathway is also involved in many 
other important biological processes. Newborn jaun-
dice needs to be modulated, rather than totally 
eliminated, and extremes should be avoided in high-
risk circumstances. Maintaining an overall balance 
is the key to good practice, even if one has to tar-
get the pathway under certain risky conditions, in 
order to control excessive bilirubin production. 
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